Alex Pasteur joined F-Prime in 2012 and is a Partner based in London. Alex focuses on investments in therapeutics and life sciences. Alex served as founding investor in the formation of ARTBIO, Inc., Tenpoint Therapeutics Holdings Ltd and Orchard Therapeutics PLC (acquired by Kyowa Kirin). He also serves on the boards of Nodthera, Inc., Genomics Ltd, Peptone Ltd, Shift Bioscience Ltd, Owkin, Inc. and Pulmocide Ltd. He is an observer on the board of Castor.

Alex previously served on the boards of Oviva AG, Acacia Pharma (acquired by Eagle Pharmaceuticals), Arvelle Therapeutics (acquired by Angelini Pharma) and as observer for Adaptimmune Therapeutics (NASDAQ: ADAP). Alex has worked in healthcare investing since 2001. Prior to joining F-Prime, Alex worked at MVM Life Science Partners LLP in the USA and Europe. Alex holds a M.A. in Natural Sciences from Cambridge University and a PhD in Chemistry from Cambridge University.